来自官方财务报表的收入、利润与现金流历史。
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $282M | $46M | $434M | $60M | $27M | $27M | $29M | $0M | $31M | $20M | $0M | $0M | $0M |
| 毛利 | — | $45M | $434M | $60M | $27M | $27M | $29M | $0M | $31M | $20M | $0M | $0M | $0M |
| 毛利率% | — | 97.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| 营业利润（EBIT） | $59M | ($158M) | $253M | ($94M) | ($131M) | ($126M) | ($65M) | ($81M) | ($42M) | ($38M) | ($33M) | ($15M) | ($9M) |
| 营业利润率% | 20.9% | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% | — | — | — |
| 净利 | $84M | ($130M) | $275M | ($79M) | ($123M) | ($126M) | ($66M) | ($77M) | ($39M) | ($37M) | ($37M) | ($15M) | ($11M) |
| 净利润率 % | 29.8% | -282.8% | 63.3% | -131.6% | -464.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — | — | — |
| EBITDA | — | ($128M) | $280M | ($76M) | ($128M) | ($123M) | ($64M) | ($77M) | ($42M) | ($37M) | ($32M) | ($15M) | ($9M) |
| 每股收益（EPS） | $1.02 | $-2.05 | $4.23 | $-1.39 | $-2.52 | $-2.71 | $-1.92 | $-2.98 | $-1.74 | $-2.09 | $-5.72 | $-2.52 | $-1.88 |
| 已发行股数 (M) | — | 64M | 65M | 57M | 49M | 46M | 34M | 26M | 22M | 18M | 7M | 6M | 6M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PTGX 交互式查看器。 /companies/us/PTGX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms